ESMO - European Society for Medical Oncology

#ESMO26: Non-pharmacological interventions, such as physical activity, dietary modification and digital tools, may be helpful to patients but can be challenging to implement effectively, as Georgios Kapetanakis explains #InsightsbyESMO ➡️ https://ow.ly/EBiW5100ZOP #CancerCare

🤖 #ESMOAI26 Autonomous AI is advancing rapidly What could it mean for oncology research, clinical workflows, and patient care? Join experts exploring the possibilities and challenges ahead. ⏰ Register by 28 October and save! 🔗 https://ow.ly/XX8U50ZXWe5 #esmomeetings

#ESMO26: Novel targeted treatments, including antibody–drug conjugates (#ADCs) and bispecific antibodies, show good responses in #immunotherapy-resistant #melanoma, although toxicity and cost are potential concerns. Read more: 🔗 https://ow.ly/fv2I5100nzS #InsightsbyESMO

#ESMO26: Detection of #ctDNA fractions with a single tumour-informed and tumour-agnostic profiling assay strongly predicted relapse and overall survival in a #LungCancer cohort from the #TRACERx programme 🔗 https://ow.ly/1wGS5100nzk #InsightsbyESMO #NSCLC #LiquidBiopsy

#ESMO26: Dostarlimab monotherapy produced high rates of clinical complete response in patients with mismatch repair deficient (#dMMR)/microsatellite-high (#MSI-H) locally advanced #RectalCancer in the phase II AZUR-1 trial 🔗 https://ow.ly/iizM5100ny7 #InsightsbyESMO #immunotherapy

#ESMO26: Emactuzumab, a novel monoclonal antibody targeting CSF-1R, rapidly reduces tumour size following a short course in patients with tenosynovial giant cell tumours (#TGCT) in the phase III TANGENT #ClinicalTrial 🔗 https://ow.ly/qghx5100nwS #InsightsbyESMO #RareCancers

Explore selected research presented at #ESMO26 across five live Congress Highlights Webinars, with expert discussion and interactive Q&A. 📅 9-13 November, daily at 18:30 CET Register: https://ow.ly/zfYs50ZY4kx #ESMOOnAir #CongressHighlights

#ESMO26: Several studies illustrate the breadth of #CellularTherapies being investigated and the challenges that will need to be addressed as they move towards wider use in the clinic. Read more 🔗 https://ow.ly/oJ1i5100nuC #InsightsbyESMO #ClinicalResearch

🎉 Congratulations to the recipients of the 2026 ESMO Fellowships and #ESMOMeritAwards. Inspiring reflections on career development highlighted the impact of #ESMOFellowships at #ESMO26.

In his #InsightsbyESMO Editorial, Dario Trapani discusses how #CancerTreatment optimisation should recognise #PatientCentred and healthcare system perspectives, including ensuring sustainable #CancerCare. Read more news and views from #ESMO26 ➡️ https://ow.ly/cWSt5100ZZ2

Positive phase III data in recurrent #EndometrialCancer were presented in a Presidential Symposium at #ESMO26 with #ADC sacituzumab tirumotecan in TroFuse-005 and with first-line pembrolizumab in KEYNOTE-C93. Read more: https://ow.ly/ly2s51003Gt #InsightsbyESMO

#ESMO26: Data from the MOIO trial were inconclusive regarding whether de-escalating #immunotherapy is beneficial after previous response to 6-month #ImmuneCheckpointInhibitor therapy in patients with a range of advanced #SolidTumours. #InsightsbyESMO ➡️ https://ow.ly/kVI851002VF

#ESMO26: Antibody–drug conjugate (#ADC) risvutatug rezetecan provides the first progress in decades in #osteosarcoma, with significant improvement in progression-free survival versus chemotherapy in the ARTEMIS-011 #ClinicalTrial #InsightsbyESMO ➡️ https://ow.ly/RS7x51000op

#ESMO26: RAS inhibitors improve survival in metastatic pancreatic ductal adenocarcinoma (#PDAC) irrespective of RAS mutational status, and combinations show benefits in the peri-operative setting, as discussed by Ignacio Garrido-Laguna #InsightsbyESMO ➡️ https://ow.ly/t8Rl510002h

#ESMO26: Single-cell and spatial profiling can map how the tumour ecosystem shifts under treatment pressure and may help to enhance understanding of treatment response and #resistance on a granular level, as discussed by James Reading #InsightsbyESMO ➡️ https://ow.ly/QIN150ZZZ5G

#ESMO26: Novel #TargetedTherapies and #CellularTherapies, such as a dual EZH1/2 inhibitor, show encouraging antitumour activity in early-phase sarcoma #ClinicalTrials, but longer follow-up is essential, as discussed by Katarzyna Kozak #InsightsbyESMO ➡️ https://ow.ly/oUz450ZZOTE

Interesting data linking adipose tissue cachexia and outcome to immunotherapy in gastric cancer #ESMO26 abstract 4252RO 👉linking host fat with tumour microenvironment and clinical outcomes through GDF-15 and exhausted CD8 #ESMOAmbassadors @myesmo.bsky.social

📣 #ESMO26: Join us at 15.30h today at the ESMO Booth Scientific Corner in Hall 10 for an expert presentation on ESMO Living Guidelines. Ask your questions and find out how ESMO Living Guidelines transform new evidence into practical recommendations! See our programme: https://ow.ly/Rmxy5100RQx

Packed room for the educational session on #pancreatic cancer #PDAC from biology to emerging therapies at #ESMO26 #ESMOAmbassadors @myesmo.bsky.social

#ESMO26: Practice-changing improvement in intracranial progression-free survival seen with the addition of tucatinib to standard therapy in HER2-positive metastatic #BreastCancer (#MBC) in the BRIDGET #ClinicalTrial. ➡️Read more https://ow.ly/2bRs50ZZO9L #InsightsbyESMO

#ESMO26: In phase III trials, izalontamab brengitecan (#BispecificADC targeting EGFR and #HER3) and ruzaltatug rezetecan (#ADC targeting HER3) showed significant efficacy in patients with locally advanced or #metastatic #EGFRmutant #NSCLC 🔗 https://ow.ly/EAs85100JUe #InsightsbyESMO

HARMONi-GI1: ivonescimab + chemo vs durvalumab + chemo in first-line advanced #BTC in China. -OS 14.9 vs 12.1 mos -PFS 8.4 vs 5.8 mos -ORR 53.8 vs 32.5% -Manageable safety profile A new standard of care in China. Do we need a trial in Western countries? #ESMO26 #ESMOAmbassadors @myesmo.bsky.social

#CancerResearch presented at #ESMO26 reflects the breadth of innovations and applications involving #ADCs, and also the complexity of #PrecisionMedicine using these #TargetedTherapies, as examined in Antonio Marra #InsightsbyESMO Editorial ➡️ https://ow.ly/kM395100Nju

HARMONi-GI1 phase 3 trial of ivonescimab + chemo in 1L advanced #BTC -OS 14.9 vs 12.1 mos HR 0.75 p 0.0031 -PFS 8.4 vs 5.8 mos HR 0.61 p<0.0001 -ORR 53.8 vs 32.5% p<0.0001 A new standard of care in China. Do we need a trial in Western countries? #ESMO26 #ESMOAmbassadors @myesmo.bsky.social

The PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy significantly improved overall survival in #BiliaryTractCancer in the phase III HARMONi-GI1 #ClinicalTrial presented in a Presidential Symposium at #ESMO26. Read more: 🔗 https://ow.ly/IvK850ZZGRI #InsightsbyESMO

#ESMO26: Promising phase III data were presented in a Presidential Symposium with the claudin 18.2 antibody–drug conjugates (#ADC) sonesitatug vedotin and arcotatug tavatecan in pre-treated #GastroOesophagealCancer. Read more: 🔗 https://ow.ly/SJ9J50ZZGNu #InsightsbyESMO

#ESMO26: Practice-changing results with savolitinib plus osimertinib after progression on osimertinib in selected patients with EGFR-mutated, MET-positive non-small cell #LungCancer (#NSCLC) in the SAFFRON trial. Check out 🔗 https://ow.ly/iblI50ZZGFM #InsightsbyESMO

#ESMO26: The potent KRAS G12C inhibitor divarasib outperforms sotorasib and adagrasib in advanced KRAS G12C-mutated non-small cell lung cancer (#NSCLC) in the phase III Krascendo 1 #ClinicalTrial. Read more 🔗 https://ow.ly/J0qE50ZZGws #InsightsbyESMO #LungCancer

IROCAS trial presented #ESMO26 Have we hit a wall in high risk pathological or ctDNA+ st III CRC (data from DYNAMIC-III? 👉intensifying with irinotecan doesn't work We need to better understand the cancer biology behind these results? #ESMOAmbassadors @myesmo.bsky.social

The incidence of #EarlyOnsetColorectalCancer is rising and evidence presented at #ESMO26 points to the tumour microenvironment having a unique immune profile that could inform future #ClinicalResearch, as discussed by Elena Elez ➡️ https://ow.ly/VjL650ZZKLB #InsightsbyESMO

#ESMO26: Disappointing results with mFOLFIRINOX chemotherapy intensification in the phase III IROCAS #ClinicalTrial reinforces how much work remains to be done in high-risk, locally advanced #ColonCancer, as discussed by Jenny Seligmann 🔗 https://ow.ly/GuV150ZZsvZ #InsightsbyESMO

Georgina Long presented the positive phase 3 INTerpath-001 study of #intismeran -a personalised mRNA-based vaccine- combined with pembrolizumab in #adjuvant #melanoma at Presidential Symposium I at #ESMO26. #ESMOAmbassadors @myesmo.bsky.social

GUCY2C one of the colorectal cancer stemness markers is going to capture the attention of the GI community in the near future. Yesterday a CART approach 🎯 was presented at #ESMO26 with promising results Others to come Watch the space! #ESMOAmbassadors @myesmo.bsky.social

#ESMO26: Promising results for antibody–drug conjugates (#ADCs) in less common cancers, including #NasopharyngealCarcinoma and #GermCellTumours add to the growing body of evidence of their benefit. Read more #InsightsbyESMO ➡️ https://ow.ly/q05i50ZZssg #DrugDevelopment

Interest is growing in multispecific antibodies to target tumour types that are unresponsive to current #immunotherapy, as illustrated by #ClinicalTrials presented at #ESMO26 in #ColorectalCancer and #ClearCellRenalCellCarcinoma 🔗 https://ow.ly/NL5a50ZZspP #InsightsbyESMO @mdcurioni.bsky.social

#ESMO26: With long-awaited positive survival outcomes for a personalised #mRNA #NeoantigenVaccine, a key question discussed by John Haanen in his Editorial is how to make #CellularTherapies practical, scalable and sustainable #InsightsbyESMO ➡️ https://ow.ly/ezcR5100KzB

#ESMO26: DASL-HiCaP and a substudy of PROTEUS phase II trials show that adding an androgen receptor pathway inhibitor (#ARPI) reduced the risk of #metastasis-free survival in very high risk localised or relapsed #ProstateCancer #InsightsbyESMO ➡️ https://ow.ly/WcXm50ZZYvv

#ESMO26: Significant improvements in overall survival in the DeLLphi-305 #ClinicalTrial with the bispecific T-cell engager #immunotherapy tarlatamab added to durvalumab could be practice-changing in extensive-stage #SCLC 🔗 https://ow.ly/muI050ZZH6K #InsightsbyESMO #LungCancer

#ESMO26: Neoadjuvant enfortumab vedotin significantly improved event-free and overall survival when added to peri-operative durvalumab for muscle-invasive #BladderCancer (#MIBC) in the phase III VOLGA #ClinicalTrial 🔗 https://ow.ly/g7KY50ZZH4m #InsightsbyESMO #ADC

#ESMO26: Intismeran autogene individualised #mRNA-based #NeoantigenVaccine therapy reduced recurrence risk by 42% in patients with resectable #melanoma treated with adjuvant pembrolizumab in the INTerpath-001 phase III #ClinicalTrial 🔗 https://ow.ly/qGzY50ZZLUF #InsightsbyESMO

#ESMO26: Investigational bispecific antibodies, such as the anti-PD-L1/VEGF-A pumitamig, are showing promise when combined with antibody–drug conjugates (#ADCs) in advanced solid tumours, as discussed by Funda Meric-Bernstam 🔗 https://ow.ly/Bsw450ZZH1b #InsightsbyESMO

Today I had the honor to discuss two important abstracts of novel treatment approaches for patients with #HCC across different stages and settings at #ESMO26. Not yet in clinical practice, but clinically relevant results. #ESMOAmbassadors @myesmo.bsky.social

#ESMO26: Adding capivasertib to abiraterone and adding abiraterone to standard care resulted in significant improvements in #ProstateCancer in the phase III CAPItello-281 and PEACE-1 #ClinicalTrials, as discussed by Elena Castro 🔗 https://ow.ly/moTe50ZZGYv #InsightsbyESMO

📣 New & updated pocket guidelines available to delegates both onsite & online. 👉 For details, grab the flyer at the entrance or the ESMO booth, check the Events app ('More' tab) or visit the 'Publications' page on the virtual congress platform. 🔗 https://ow.ly/uWTl50ZToZI

Happening today: EACR-ESMO Joint Session 'What oncologists should know about molecular oncology' #ESMO26 If you're at the ESMO Congress today, stop by and hear from Chiara Ambrogio, Sophie Postel-Vinay, and Jean Christophe Marine. Room: Barcelona Auditorium - Hall 9 | Time: 12:00 - 12:50

📣 #ESMO26: Join us at the ESMO Booth Scientific Corner! Watch expert presentations and ask your questions: explore how ESMO scientific resources can inform your daily practice! See the programme: https://ow.ly/srgp5100JRO

#ESMO26: Pembrolizumab plus chemotherapy reduced the risk of PFS by 26% in PD-L1-positive, HR-positive #AdvancedBreastCancer after failure on endocrine therapy in the phase III KEYNOTE-B49 #ClinicalTrial 🔗 https://ow.ly/YQbv50ZZGX6 #BreastCancer #InsightsbyESMO Paolo Tarantino, MD

#ESMO26: Final results from the TALENT #ClinicalTrial show low pathological complete response rates with the antibody–drug conjugate (#ADC) trastuzumab deruxtecan in HR-positive, HER2-low #EarlyBreastCancer, as discussed by Peter Dubsky. #InsightsbyESMO ➡️ https://ow.ly/SZoK50ZZXMf

Don't miss out on the latest news, resources, and opportunities from ESMO. Review your myESMO profile and communication preferences to continue receiving newsletters and other relevant updates. 🔗 https://ow.ly/9RC351002Bi

#ESMO26: Phase II data suggest selected patients with localised gastro-oesophageal adenocarcinoma (#GEA) may benefit from a dostarlimab watch-and-wait strategy that can achieve good responses without surgery 🔗 https://ow.ly/Mu2w50ZZiKG #InsightsbyESMO #GICancers